Letter by Machado-Alba et al Regarding Article, “Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation: Systematic Review and Meta-Analysis”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
We have reviewed with great interest the article by Bai et al1 where the safety and effectiveness of rivaroxaban, dabigatran, and warfarin were compared for the prevention of thromboembolic events using real-world evidence. It was found that the effectiveness of rivaroxaban is superior to that of warfarin in new users with atrial fibrillation, although it was similar when the patient changed from warfarin to rivaroxaban.
Previously, it has been described that the effectiveness of the nonvitamin K oral anticoagulants versus warfarin can vary according to the geographic region where it is evaluated.2 In Colombia, we lack studies comparing the effectiveness of the nonvitamin K oral anticoagulants versus warfarin in the prevention of thromboembolic …